Advertisement

Topics

Arcus Biosciences secures funding to advance clinical programs for AB928

03:07 EST 14 Nov 2017 | Pharmaceutical Business Review

Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m.

Original Article: Arcus Biosciences secures funding to advance clinical programs for AB928

NEXT ARTICLE

More From BioPortfolio on "Arcus Biosciences secures funding to advance clinical programs for AB928"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...